AI Article Synopsis

  • Identified a protein called TsSP from Trichinella spiralis that may help it invade hosts and grow, with potential as a vaccine target.
  • Conducted tests to measure the expression of TsSP during different larval stages and found that it binds to and enters intestinal cells.
  • Immunizing mice with TsSP significantly reduced the number of adult worms and larvae, demonstrating TsSP's role in parasite invasion and indicating its potential for vaccine development against Trichinella infections.

Article Abstract

In our previous work, a Trichinella spiralis putative serine protease (TsSP) was identified from ES products of T. spiralis intestinal infective larvae (IIL) and adult worms (AW) by immunoproteomics: it was highly expressed in IIL compared with muscle larvae (ML). In this study, the TsSP biological characteristics in larval invasion and growth were identified and its potential as a vaccine target against Trichinella infection were investigated. Expression of TsSP at various developmental phases (newborn larvae, ML, IIL, and AW) was detected by qPCR, immunofluorescent test and Western blotting. The rTsSP could specifically bind to the intestinal epithelial cell (IEC) membrane and enter into the cytoplasm. Anti-rTsSP serum suppressed the larval invasion of enterocytes in a dose-dependent mode, and killed newborn and ML of T. spiralis, decreased larval infectivity and development in the host by an ADCC-mediated mechanism. Immunization of mice with rTsSP produced a Th2 predominant immune response, and resulted in a 52.70% reduction of adult worms at 5 days post-infection (dpi) and a 52.10% reduction of muscle larvae at 42 dpi. The results revealed there was an interaction between TsSP and the host's IEC; TsSP might be a pivotal protein for the invading, growing and parasiting of this nematode in the host. Vaccination of mice with rTsSP elicited immune protection, and TsSP is a potential target molecule for vaccines against enteral Trichinella infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043985PMC
http://dx.doi.org/10.1186/s13567-018-0555-5DOI Listing

Publication Analysis

Top Keywords

putative serine
8
serine protease
8
trichinella spiralis
8
elicited immune
8
immune protection
8
larvae iil
8
adult worms
8
muscle larvae
8
larval invasion
8
trichinella infection
8

Similar Publications

Glimepiride (GLM) is one of the potential antidiabetic drugs used in clinics for a long time. It is currently used in combination with metformin along with other drugs, but has shown various complications in patients from long-term use. Thus, the hypothesis is to use a lower dose of GLM with a non-toxic class of flavonoid, naringin (NARN), for better therapy with minimal side-effects.

View Article and Find Full Text PDF

Receptor-independent regulation of Gα13 by alpha-1-antitrypsin C-terminal peptides.

J Biol Chem

December 2024

Department of Biosystems Science, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; Department of Mammalian and Regulatory Networks, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; Department of Homeostatic Medicine, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address:

Alpha-1-antitrypsin (AAT), a circulating serine protease inhibitor, is an acute inflammatory response protein with anti-inflammatory functions. The C-terminal peptides of AAT are found in various tissues and have been proposed as putative bioactive peptides with multiple functions, but its mechanism of action remains unclear. We previously reported that a mouse AAT C-terminal peptide of 35 amino acids (mAAT-C) penetrates plasma membrane and associates guanine nucleotide-binding protein subunit alpha 13 (Gα13).

View Article and Find Full Text PDF

AMPylation is a post-translational modification (PTM) whereby adenosine monophosphate (AMP) from adenosine triphosphate (ATP) is transferred onto protein hydroxyl groups of serine, threonine, or tyrosine. Recently, an actin-dependent AMPylase namely LnaB from the bacterial pathogen Legionella pneumophila was found to AMPylate phosphate groups of phosphoribosylated ubiquitin and Src family kinases. LnaB represents an evolutionarily distinct family of AMPylases with conserved active site Ser-His-Glu residues.

View Article and Find Full Text PDF

New metabolic insights into the mechanism of ifosfamide encephalopathy.

Biomed Pharmacother

December 2024

Department of Biomedical Research, University of Bern, Bern, Switzerland; Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA, USA. Electronic address:

Ifosfamide causes neurotoxicity, including sometimes fatal encephalopathy, in a small number of patients. Why and how this occurs is not fully understood. It is generally believed that N-dechloroethylation of ifosfamide to 2-chloroacetaldehyde is the cause.

View Article and Find Full Text PDF

Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales.

J Antimicrob Chemother

December 2024

Norwich Medical School, University of East Anglia, Floor 2, Bob Champion Research & Educational Building, James Watson Road, Norwich NR4 7UQ, UK.

Background: Antibiotic resistance complicates treatment of urinary infections, particularly when these ascend above the bladder, with few oral options remaining. New oral β-lactamase inhibitor combinations present a potential answer, with ceftibuten/avibactam-now undergoing clinical trials-widely active against strains with ESBLs and serine carbapenemases. To inform its development we undertook mutant selection studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!